Eduardo Marban, MD, PhD

Dr. Eduardo Marban | Executive Director, Smidt Heart Institute @CedarsSinai Views are my own, not institutional policy!

[Ahmed Ibrahim @TheIbrahimLab]

An elegant talk by @MarbanLab at Grand Rounds on novel RNA drugs #exomers and our long, winding, and fun research arc. To the clinic or bust!

[Eduardo Marban, MD, PhD @MarbanLab]

Tune in on Tuesday, Oct 20th at 8 am PDT to hear the latest updates on our work with #exomers

Microsoft Teams meeting
Join: https://t.co/HT13f3Csvn
Meeting ID: 212 993 917 099 964
Passcode: i8iF9Rb7

[Eduardo Marban, MD, PhD @MarbanLab]

Tune in on Tuesday, Oct 20th at 8 am PDT to hear the latest updates on our work with #exomers

Microsoft Teams meeting
Join: https://t.co/HT13f3Csvn
Meeting ID: 212 993 917 099 964
Passcode: i8iF9Rb7

[Eduardo Marban, MD, PhD @MarbanLab]

@CardioOncology @nyulangone @UCSFCardiology @glennfishman Power couple! 👊

[Eduardo Marban, MD, PhD @MarbanLab]

@Paulwnoblemd Congratulations Paul! What an honor! 👏👍👊

[Eugenio Cingolani, MD @EugenioCingolan]

#ACM #ARVC #VT #NewTherapies @ICBAonline @CedarsSinaiMed @CedarsSinai #LATAM 🇦🇷

[Eduardo Marban, MD, PhD @MarbanLab]

This week’s #journalclub featured @T_Ikenouchi on modulators of #cardiomyocyte proliferation (yes, there are even more lurking out there), @AleCiulloPhD on cell-cell #mitochondrial transfer in #FreidreichsAtaxia (who’d have thought it happens frequently enough to make a therapeutic difference?), and me discussing a phase 1 trial of an anti-RAGE #siRNA for #asthma (nice template for our own upcoming FIH #exomer trials).

[Eduardo Marban, MD, PhD @MarbanLab]

Terrific lab meeting this week by @ke_liaoPhD on the mechanism of #depression, which afflicts one third of patients after a #HeartAttack. Amazing discoveries involving #EVs, circular #RNA and depletion of miRs. We even have a prototype therapeutic candidate! Exciting times…

[Eduardo Marban, MD, PhD @MarbanLab]

Late Breaking clinical trial #HOPE-3 OLE shows striking benefits of #deramiocel sustained over two years of therapy, and 76% slowing of #Duchenne myopathy progression in those who crossed over from placebo to deramiocel after one year. Work of ace #DMD trialist Craig McDonald highlighted at the @WorldMuscleSoc meeting in Hiroshima. Trial sponsored by @Capricor based on intellectual property from my team at Cedars-Sinai.

[Eduardo Marban, MD, PhD @MarbanLab]

Enjoyed my visit to @dgsomucla and the opportunity to discuss #exomers for #scleroderma, #Duchenne and #arrythmogenic #cardiomyopathy

@TheIbrahimLab @AleCiulloPhD @rrogerslab @EugenioCingolan @soussi_salwa @XMichaelJonesMD

[Mohammad Reza Hatamnejad, MD, MPH @MR_Hatamnejad]

Delighted to have @MarbanLab for an inspiring talk on translating cardiosphere-derived cell biology into RNA therapeutics. Fascinating insights into extracellular vesicles, Y RNA, macrophage reprogramming, tissue repair, and TY1; from discovery to clinical translation. #UCLA

[Eduardo Marban, MD, PhD @MarbanLab]

Looking forward to sharing our work on #exomers with friends and colleagues at @dgsomucla next week!

[Eduardo Marban, MD, PhD @MarbanLab]

Proud of my two former trainees (the poster, Eugenio, and the speaker, Tetsuo)!!

[Eugenio Cingolani, MD @EugenioCingolan]

Fantastic lecture on #AF by Prof Tetsuo Sasano from Tokyo Institute of Science 🇯🇵 @CedarsSinaiMed - from basic mechanisms to improving detection on a #taxiride 🚕 or #hotelbed 🏨 CedarsSinai @APHRSOfficial @HRSonline

[JCI insight @JCI_insight]

Suggesting a novel therapy for #SystemicSclerosis: https://t.co/EdUt8cSVrO

Eduardo Marbán & team @Marbanlab @CedarsSinai report that an orally delivered noncoding RNA (TY1) reduces inflammation and organ fibrosis in models of systemic sclerosis through inhibition of the cGAS/STING axis. The authors employed in vitro and in vivo models and evaluated skin, lung, and heart.
The video shows TY1 treatment in preclinical models of systemic sclerosis.
@AleCiulloPhD @TheIbrahimlab @the_asci

[Waggoner Lab @LabWaggoner]

Noncoding RNA TY1 reverses fibrosis in systemic sclerosis by attenuating the cGAS/STING pathway @JCI_insight @MarbanLab
https://t.co/BlZxO31Pj4

[Eduardo Marban, MD, PhD @MarbanLab]

Excited to share our latest paper in @JCI_insight, with @XMichaelJonesMD & @TheIbrahimLab : #TY1, an #RNA #exomer drug, reverses the key disease manifestations of #scleroderma in 2 mouse models & in human #SSc cells. The drug works well orally & has unprecedented disease-modifying bioactivity in this horrible disease. Next step: clinical trials!
https://t.co/0EXDWd7CqI

[Eduardo Marban, MD, PhD @MarbanLab]

@cingolani_oscar Maybe it’s because you’re dead if you took the wrong chance? 🤔

[Eugenio Cingolani, MD @EugenioCingolan]

Percutaneous Atrial Delivery of TBX18 Creates a Stable Supraventricular Biological Pacemaker in Porcine Sick Sinus Syndrome | JACC: Clinical Electrophysiology https://t.co/9EaRlOFkHQ

@JACCJournals #JACCEP #Biopacer
#Biopace #CRM #RhythmsAndMore

[Eugenio Cingolani, MD @EugenioCingolan]

New work on #Biopacer to treat #SAN dysfunction in a swine model of #SAN disease published in #JACCEP @JACCJournals - #Biopace #CRM

[Eduardo Marban, MD, PhD @MarbanLab]

Lancet paper provides important independent validation of the HOPE-3 trial. Let’s get #deramiocel to all #Duchenne patients in dire need.

[Capricor Therapeutics @Capricor]

We're pleased to share that @TheLancet has published results from Capricor's Phase 3 HOPE-3 trial evaluating Deramiocel in #Duchenne muscular dystrophy.

The independent peer-reviewed publication validates the trial's design, statistical methodology and findings. HOPE-3 met its primary endpoint, with Deramiocel slowing upper limb function decline by 54 percent versus placebo (PUL 2.0, p=0.03) and demonstrating a clinically meaningful cardiac benefit.

Read more here: https://t.co/WPBkXv0Ws9

We are grateful to the patients, families, investigators and study teams who made this research possible.